Faculty profile

Arielle Elkrief

ResearcherUniversité de Montréal

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université de Montréal directory, so their courses may be missing. Find their university profile.

Arielle Elkrief

Researcher

Health Sciences

Université de Montréal

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
32 publications in the last five years, latest in 2026.
Senior (last) author on 5 recent papers, a sign of leading a research group.
Principal investigator on 2 research grants (2 CIHR), most recently in 2025.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Cancer Progression Lung Cancer Lung Microbiome Tumor Microbiome

Latest papers

Dietary intervention through bacterial-derived butyrate elicits anti-tumor activity and increases anti-PD-1 response.
Gut microbes · 2026
Diet-microbiome synergy underlies obesity-associated immunotherapy efficacy.
Nature · 2026
Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.
The Lancet. Oncology · 2026

All 50 publications

Latest funding

Environmental eXposure Profiling for Signatures of Early ColoRectal Cancer (EXPOSE-CRC)
CIHR · 2025 · Co-investigator
$1,000,000
Defining the Lung and Tumor Microbiomes as Drivers of Non-Small Cell Lung Cancer Development and Progression
CIHR · 2025 · Nominated PI
$918,000
Defining the Lung and Tumor Microbiomes as Drivers of Non-Small Cell Lung Cancer Development and Progression
CIHR · 2025 · Nominated PI
$25,000

All 4 grants and awards

50 publications.

Dietary intervention through bacterial-derived butyrate elicits anti-tumor activity and increases anti-PD-1 response.

Benlaïfaoui M, Richard C, Hunter S, Méndez-Salazar EO, Kourtian S, Malo J, Prifti DK, Ponce M, Khalfi S, Belkaïd W, Messaoudene M, Boidot R, Truntzer C, Girhinghelli F, Lehoux-Duboix C, Ancuta P, Elkrief A, Marcil V, Routy B

Gut microbes2026

DOI: 10.1080/19490976.2026.2699457 PMID: 42454784

Diet-microbiome synergy underlies obesity-associated immunotherapy efficacy.

Desharnais L, Swaby A, Messaoudene M, Doré S, Yu MW, Fiset B, Breton V, Ponce M, Hu Y, Wilson L, Sorin M, Wang Y, Dewar K, Pollak M, Elkrief A, Routy B, Walsh LA, Quail DF

Nature2026

DOI: 10.1038/s41586-026-10750-x PMID: 42420462

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

Brunetti L, Santo V, Pinato DJ, Citarella F, Orlando S, Acker F, Colella V, Ricciuti B, Naidoo J, Nassar A, Wakelee HA, Takada K, Naqash AR, Garassino MC, Greco C, Ramella S, Pantano F, Tonini G, Vincenzi B, Arlunno B, Remon J, Parisi C, Planchard D, Besse B, Desilets A, Routy B, Elkrief A, Barlesi F, Derosa L, Cortellini A

The Lancet. Oncology2026

DOI: 10.1016/s1470-2045(26)00191-9 PMID: 42398520

Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling.

Suissa D, Fidelle M, Reich E, Pham TN, Thomas S, Björk JR, Liu P, Zhao L, Kitaoka K, Piard E, Lebhar I, Tian AL, Thelemaque C, Alves Costa Silva C, Deutsch E, Loriot Y, Segata N, Piccinno G, Hospers GAP, Maleki Vareki S, Silverman MS, Lenehan JG, Bataille V, Boulate D, Kuznetsova T, Weersma RK, Messaoudene M, Durand S, van der Aalst CM, de Koning HJ, Schuler-Thurner B, de Vries IJM, Rafie E, Saliby RM, Machaalani M, Haferkamp S, Schilling B, Porcari S, Ciccarese C, Iacovelli R, Cremolini C, Choueiri TK, Elkrief A, Kroemer G, Heinzerling L, Chamoto K, Ianiro G, Routy B, Derosa L, Paragios N, Zitvogel L

Nature medicine2026

DOI: 10.1038/s41591-026-04481-9 PMID: 42350644

Neoadjuvant Chemotherapy-Immunotherapy in Non-Small Cell Lung Cancer: Can Positron Emission Tomography Scan Predict Complete Pathologic Response?

Seitlinger J, Salko O, Bulgarelli Maqueda L, Meng A, Têtu M, Desilets A, Owen S, Shieh B, Wong A, Ofiara L, Agulnik J, Fiset PO, Malo J, Blais N, Florescu M, Tehfe M, Ferraro P, Nasir B, Cools-Lartigue J, Najmeh S, Juneau D, Elkrief A, Ferri L, Routy B, Liberman M, Spicer JD

The Annals of thoracic surgery2026

DOI: 10.1016/j.athoracsur.2025.09.051 PMID: 41167577

Metagenomics and culturomics reveal the dual role of the gut microbiome in the development of immune-related toxicities and the efficacy of immune checkpoint inhibitors in cancer.

Diop K, Benlaïfaoui M, Hunter S, Méndez-Salazar EO, Hakozaki T, Richard C, Prifti DK, Kourtian S, Proulx-Rocray F, Naimi S, Ponce M, Messaoudene M, Cauchois F, Belkaid W, Bataille V, Lee K, Mihalcioiu C, Watson IR, Elkrief A, Routy B

Microbiome2026

DOI: 10.1186/s40168-026-02419-4 PMID: 42083059

Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial.

Duttagupta S, Messaoudene M, Hunter S, Desilets A, Jamal R, Mihalcioiu C, Belkaid W, Marcoux N, Fidelle M, Suissa D, Ponce M, Geiger M, Malo J, Piccinno G, Punčochář M, Filin A, Heidrich V, Rusu D, Mbaye B, Durand S, Ben Aissa I, Puller V, de Lahondès R, Blais N, Tehfe M, Owen S, Bélanger K, Parvathy SN, Shieh B, Raphael J, Lenehan J, Breadner D, Rothenstein J, Rozza N, Maillou J, Nili S, Prifti DK, Pinto F, Armanini F, Kim-Schulze S, Marron TU, Kroemer G, Derosa L, Zitvogel L, Silverman M, Segata N, Maleki Vareki S, Routy B, Elkrief A

Nature medicine2026Senior author

DOI: 10.1038/s41591-025-04186-5 PMID: 41606121

Multi-Institutional CT Scan-Based Radiomics for Predicting Tumor PD-L1 Expression in Patients with Advanced and Limited Non-Small Cell Lung Cancer.

Saber R, Tonneau M, Salko O, Liberman M, Malo J, Elkrief A, Turcotte S, Bouchard N, Joubert P, Kadoury S, Routy B

Cancers2026

DOI: 10.3390/cancers18040552 PMID: 41749806

p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program.

Wang M, Bieging-Rolett KT, Kaiser AM, Brady CA, Lockhart JH, Ferreira S, Nguyen KT, Rajeevan A, Evans SA, Zhao T, Raj N, Elkrief A, Tischfield SE, Ladanyi M, Ozawa MG, Bui NQ, Chen CT, Flores ER, Attardi LD

Cancer discovery2026

DOI: 10.1158/2159-8290.cd-25-0525 PMID: 41115251

Antibiotic-related dysbiosis in cancer immunotherapy: from preclinical insights to practice-changing evidence.

Routy B, Rafie E, Elkrief A

Nature cancer2025Senior author

DOI: 10.1038/s43018-025-01055-5 PMID: 41372472

Something wrong or missing on this profile? Suggest a correction

Arielle Elkrief

Research

Latest papers

Latest funding

Dietary intervention through bacterial-derived butyrate elicits anti-tumor activity and increases anti-PD-1 response.

Diet-microbiome synergy underlies obesity-associated immunotherapy efficacy.

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling.

Neoadjuvant Chemotherapy-Immunotherapy in Non-Small Cell Lung Cancer: Can Positron Emission Tomography Scan Predict Complete Pathologic Response?

Metagenomics and culturomics reveal the dual role of the gut microbiome in the development of immune-related toxicities and the efficacy of immune checkpoint inhibitors in cancer.

Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial.

Multi-Institutional CT Scan-Based Radiomics for Predicting Tumor PD-L1 Expression in Patients with Advanced and Limited Non-Small Cell Lung Cancer.

p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program.

Antibiotic-related dysbiosis in cancer immunotherapy: from preclinical insights to practice-changing evidence.

Environmental eXposure Profiling for Signatures of Early ColoRectal Cancer (EXPOSE-CRC)

Defining the Lung and Tumor Microbiomes as Drivers of Non-Small Cell Lung Cancer Development and Progression

Defining the Lung and Tumor Microbiomes as Drivers of Non-Small Cell Lung Cancer Development and Progression

Harnessing Humoral Immunity and Bacterial Loss for the Development of a Live Biotherapeutic Product to Improve Microbiome and Immunotherapy Response in Lung Cancer

Frequent collaborators

Bertrand Routy

Catalin Mihalcioiu

Philippe Joubert

Gerald Batist

Bastien Castagner

Gerald Batist

Réjean Lapointe

Wilson Miller

Marie Hudson

Lorenzo Ferri

Pierre-Olivier Fiset

Michael Silverman

Samuel Kadoury

Morag Park

Geoffrey Liu

Michael Pollak

Yves Brun

Samuel Kadoury

Swneke Bailey

Adrian Sacher

Thierry Muanza